.jpg)
- Hikma Pharmaceuticals to join FTSE 100
- Inmarsat to enter FTSE 250 in rebalance
FTSE Russell, the global index provider, confirms today that Hikma Pharmaceuticals will be joining the FTSE 100 Index. In the rebalance, Inmarsat will enter the FTSE 250 Index.
The changes announced today are part of the impartial quarterly reviews endorsed by the independent FTSE Russell Europe, Middle East and Africa (EMEA) Regional Equity Advisory Committee. The rules-driven reviews ensure the indexes continue to portray an accurate reflection of the market they represent, and form an essential component to the management of the indexes.
The FTSE 250 Index will see the following changes (in alphabetical order), in addition to the amendments described above:
|
Entering FTSE 250 Index |
Exiting FTSE 250 Index |
| Ascential CMC Markets Countryside Properties CYBG Hill & Smith Hldgs Metro Bank Smurfit Kappa Group |
Highbridge Multi-Strategy Fund Interserve Jimmy Choo Lookers Melrose Industries Northgate Ophir Energy |
FTSE Russell operates a reserve list for the FTSE 100 Index, to be used in the event of a corporate action occurring between reviews e.g. merger, acquisition, delisting or suspension. In such cases, the reserve list constituent with the largest market capitalisation (on the date of the corporate action) will replace the outgoing constituent. With immediate effect, the following reserve list for FTSE 100 will be used (in alphabetical order):
• Aberdeen Asset Management Group
• Auto Trader Group
• Croda International
• Rightmove
• Smiths Group
• Smurfit Kappa Group
All changes from this review will be implemented at the close of business Friday, 17 June 2016 and take effect from the start of trading on Monday, 20 June 2016.
